Cargando…

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly

Acromegaly is a hormonal disorder resulting from excessive growth hormone (GH) secretion frequently produced by pituitary adenomas and consequent increase in insulin‐like growth factor 1 (IGF‐I). Elevated GH and IGF‐I levels result in a wide range of somatic, cardiovascular, endocrine, metabolic and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venegas‐Moreno, Eva, Vazquez‐Borrego, Mari C., Dios, Elena, Gros‐Herguido, Noelia, Flores‐Martinez, Alvaro, Rivero‐Cortés, Esther, Madrazo‐Atutxa, Ainara, Japón, Miguel A., Luque, Raúl M., Castaño, Justo P., Cano, David A., Soto‐Moreno, Alfonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824369/ https://www.ncbi.nlm.nih.gov/pubmed/29266696 http://dx.doi.org/10.1111/jcmm.13440

Ejemplares similares

E‐cadherin expression is associated with somatostatin analogue response in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2019)

MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas
por: Soto, Alfonso, et al.
Publicado: (2019)

Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features
por: Flores-Martinez, Álvaro, et al.
Publicado: (2020)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
por: Kontogeorgos, George, et al.
Publicado: (2022)

Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly
por: VALEA, ANA, et al.
Publicado: (2015)

Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
por: Coelho, Maria Caroline Alves, et al.
Publicado: (2019)

The Effect of Long Acting Somatostatin Analogue SMS 201-995 in Acromegaly
por: Choi, Chul Joon, et al.
Publicado: (1987)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
por: Follin, Cecilia, et al.
Publicado: (2016)

Neurocognitive Function in Acromegaly after Surgical Resection of GH-Secreting Adenoma versus Naïve Acromegaly
por: Martín-Rodríguez, Juan Francisco, et al.
Publicado: (2013)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
por: Strasburger, Christian J, et al.
Publicado: (2016)

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement
por: Peverelli, Erika, et al.
Publicado: (2015)

Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors
por: Pedraza‐Arevalo, Sergio, et al.
Publicado: (2021)

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study
por: Shen, Ming, et al.
Publicado: (2018)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
por: Sala, E., et al.
Publicado: (2021)

Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma
por: Sanjuan-Sanjuan, Alba, et al.
Publicado: (2021)

Erratum to “Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study”
por: Shen, Ming, et al.
Publicado: (2019)

Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
por: Haris, Basma, et al.
Publicado: (2020)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
por: Liu, Wenjuan, et al.
Publicado: (2017)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies
por: Yang, Chengxian, et al.
Publicado: (2019)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Somatostatin Analogues for Receptor Targeted Photodynamic Therapy
por: Kaščáková, Slávka, et al.
Publicado: (2014)

Prescription patterns of long-acting somatostatin analogues
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2017)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly
por: Ciganoka, Darja, et al.
Publicado: (2011)

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course
por: Pichler, Robert, et al.
Publicado: (2021)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features
por: Vázquez-Borrego, Mari C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tutu15th249d3q40cbm90cs9ov